GATC Health Corp | April 22, 2022
GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform.
Prodrugs are physiologically inactive chemicals that are converted to drugs in the body. Aspirin, Plavix, and Prednisone are just a few examples. The novel new prodrug developed by GATC Health is meant to trigger programmed cell death in malignant cancer tissues and could be used to treat glioblastoma brain tumors.
Due to the difficulty of delivering and selecting drug-target interactions, this unique technique of treatment has not been conceivable before, but it has the potential to improve safety and selectivity. Furthermore, this new prodrug formulation has the potential to significantly lessen the collateral harm produced by past iterations of chemical agents employed to treat cancer. This style, according to the business, will lead to many more advances in innovative cancer therapies.
I am very excited that we are continuing to expand our portfolio at GATC Health and entering in oncology with this innovative platform to meet unmet needs of cancer patients, Glioblastoma accounts for half of all the cancerous brain tumors in adults. We see about 12 to 18 months average survival time for these patients with only 5% of patients surviving more than five years, highlighting the unmet need for innovation for these patients. Our new prodrug has the potential to differentiate between glioblastoma cells and healthy neuron growth, preventing replication of cancer cells for glioblastoma. This new technology may also be used for other tumors. Global spending on therapeutics and supportive care of cancer is continuing to grow and be is expected to reach $200 billion in 2022. With growing incidence of cancer in patients, oncology is the focus area for the 10 largest pharma companies, and we are looking forward to partnering with them to bring glioblastoma patients and other cancer patients a safe, effective cure."
Preetaman Wadhwa, the company's Chief Marketing Officer.
Innatoss Laboratories | September 15, 2020
Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service of this kind for the public. "Our collaboration with GenScript is a crucial step toward offering high-quality, innovative products to combat the COVID-19 pandemic, which poses a global threat to public health," said Dr. Anja Garritsen, CEO of Innatoss. "cPass ™ uses a novel test method that is capable of detecting the presence of virus-specific neutralizing antibodies. The test would be useful in determining the longevity of potential immunity both in individuals and the broader population, and facilitating development of vaccines and monoclonal antibody therapy development. It will become the key test to monitor titers once vaccination has been implemented." Innatoss recently performed a study in Kessel, a city in the south of the Netherlands that was severely affected during the first wave of COVID-19, to determine the longevity of binding antibodies versus neutralizing antibodies in individuals. The people were initially tested 2-4 months post infection using a rapid test for IgG and IgM levels, and then were retested 2-3 months later. Afterwards, the patients' samples were tested for neutralizing antibodies using the GenScript cPass™ kit. In 90 percent of the cases the binding antibody levels dropped significantly over time while the level of functional antibodies (neutralizing antibodies) was stable in 70 percent of those tested.
Xylyx Bio | September 30, 2020
Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to humans. Commonly used assays have limited ability to predict how a drug candidate will act when introduced into patients, costing biopharma companies billions in the quest to determine which drugs will be most effective. To address this, Xylyx Bio now offers specialized contract R&D services based on its highly predictive IN MATRICO™ platform. Xylyx Bio's custom assays incorporate human disease-specific extracellular matrix (ECM) substrates combined with clinically relevant informatics to better represent human biology and reliably de-risk drug discovery through early efficacy signals that simultaneously reduce costs and development time.